Review
Pharmacology & Pharmacy
Congshun Ma, Qianru Xiang, Ge Song, Xuefei Wang
Summary: Polycystic ovary syndrome (PCOS) is a reproductive endocrine disease with no specific drug treatment. Quercetin (QUR), a flavonoid, has potential therapeutic effects for PCOS patients. However, the mechanisms of QUR in PCOS patients remain unclear.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Health Care Sciences & Services
Mardia Lopez-Alarcon, Victor Saul Vital-Reyes, Eduardo Almeida-Gutierrez, Jorge Maldonado-Hernandez, Salvador Flores-Chavez, Juan Manuel Dominguez-Salgado, Jose Vite-Bautista, David Cruz-Martinez, Aly S. Barradas-Vazquez, Ricardo Z'Cruz-Lopez
Summary: Polycystic ovary syndrome (PCOS) is often accompanied by metabolic disturbances related to androgen excess and obesity. This study found that obesity is strongly associated with biomarkers related to glucose and liver metabolism, while free testosterone (FT) is only correlated with glucose and liver-related indicators. Women with obesity are at a higher risk of metabolic disorders compared to lean women, regardless of hyperandrogenemia.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Review
Pharmacology & Pharmacy
Anastasia Vatopoulou, Maria-Eleni Dionelli, Alexis Papanikolaou, Sonia Grover
Summary: Adolescents with PCOS exhibit various cardiometabolic risk factors, suggesting the importance of early identification for preventing cardiovascular diseases in adulthood.
CURRENT PHARMACEUTICAL DESIGN
(2021)
Review
Pharmacology & Pharmacy
Hongying Shan, Renxin Luo, Xuanying Guo, Rong Li, Zhenhong Ye, Tianliu Peng, Fenting Liu, Zi Yang
Summary: Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder in women, which is associated with infertility, menstrual irregularities, endometrial hyperplasia, and obesity. The disease and its complications are closely related to local oxidative stress imbalance in the endometrium, affecting endometrial receptivity.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Endocrinology & Metabolism
Jiayue Liu, Ying Liu, Xiaoliang Li
Summary: Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age, characterized by ovulation disorders, high androgen levels, and insulin resistance. The pathogenesis of PCOS is still unclear. Intestinal flora, known as the second genome of human beings, is closely linked to metabolic diseases, immune diseases, and infectious diseases. There is increasing evidence that intestinal flora can regulate insulin synthesis and secretion, affect androgen metabolism and follicular development, and play a role in chronic inflammation and obesity. The imbalance of intestinal flora, related to changes in microbial diversity and interactions with host cells, is associated with the occurrence and development of PCOS. Modulating intestinal flora may offer a potential direction for PCOS treatment.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Review
Medical Laboratory Technology
Huiqing Liu, Xingqi Meng, Jinyuan Wang, Yi Wei, Jinru Tang, Xiaocan Lei, Weiguo He, Suyun Li
Summary: PCOS is an endocrinemetabolic disease affecting reproductive aged women, potentially leading to various complications. Recent studies have identified a protein called SAA that may be associated with PCOS, serving as a potential inflammatory biomarker.
CLINICA CHIMICA ACTA
(2021)
Article
Endocrinology & Metabolism
Chuan Xing, Han Zhao, Jiaqi Zhang, Bing He
Summary: The study aimed to observe the effects of MET monotherapy and MET plus LIRA combination therapy on gonadal and metabolic profiles in overweight patients with PCOS. The results showed that both MET monotherapy and MET plus LIRA combination therapy improved glucose metabolism and relieved insulin resistance in overweight patients with PCOS. Furthermore, MET plus LIRA combination therapy was more effective in improving reproductive abnormalities and hyperandrogenemia compared to MET monotherapy.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Chang Shan, Yu-chen Zhu, Jie Yu, Yi Zhang, Yu-ying Wang, Nan Lu, Jie Cai, Wei Liu, Tao Tao
Summary: This study found that Chinese women with PCOS have lower levels of vitamin D compared to controls, especially in those with hyperandrogenemia. Higher levels of 25(OH)D were independently associated with lower risks of hyperandrogenemia.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Dongxu Wang, Nan Nan, Hao Bing, Bing He
Summary: Obese patients with PCOS are more prone to develop NAFLD. Compared to the control group, the obese PCOS group showed significant increases in ALT, AST, CAP, TG, TC, LDL-C, TT, FAI, FIns, and HOMA-IR levels, along with lower HDL-C and SHBG levels. Liver CAP in PCOS patients with obesity was positively correlated with ALT, AST, TG, TT, FAI, FIns, and HOMA-IR, and negatively correlated with SHBG. Logistic regression analysis showed that TG, TT, FIns, and HOMA-IR were risk factors for NAFLD, while TT was an independent risk factor for NAFLD in PCOS patients with obesity.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
W. Colin Duncan, Linda M. Nicol, Rosie O'Hare, Jason Witherington, Jason A. Miranda, Bruce K. Campbell, Jennifer L. Thomas, Michael T. Rae
Summary: Although the ovary is richly innervated, there is no evidence to suggest that sympathetic nerves play a role in ovarian function or the growth and survival of small follicles.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Salvatore Giovanni Vitale, Anna Maria Fulghesu, Mislav Mikus, Rafal Watrowski, Maurizio Nicola D'Alterio, Li-Te Lin, Mohsin Shah, Enrique Reyes-Munoz, Thozhukat Sathyapalan, Stefano Angioni
Summary: MicroRNAs (miRNAs) play crucial regulatory roles in tissue development, differentiation, and metabolic processes. In the context of PCOS, altered miRNA levels have been associated with hormonal changes, glucose and lipid metabolism, and fertility issues. This systematic review provides an overview of miRNA expression, hormonal changes, and metabolic correlations in PCOS, highlighting the potential of miRNAs as therapeutic targets and diagnostic markers.
Review
Physiology
Zhu Xue, Juanli Li, Jiaxing Feng, Han Han, Jing Zhao, Jiao Zhang, Yanhua Han, Xiaoke Wu, Yuehui Zhang
Summary: The endometrium is shed periodically in response to hormone secretion, with PCOS patients at risk for disrupted endometrial function due to endocrine and metabolic abnormalities. This can lead to various complications associated with PCOS.
FRONTIERS IN PHYSIOLOGY
(2021)
Article
Medicine, Research & Experimental
Yi -Fen Chiang, I. -Cheng Lin, Ko-Chieh Huang, Hsin-Yuan Chen, Mohamed Ali, Yun-Ju Huang, Shih-Min Hsia
Summary: This study investigated the therapeutic effect of caffeic acid on PCOS and its underlying molecular mechanism. The results showed that caffeic acid could inhibit oxidative stress and improve PCOS-related complications by modulating ER stress.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Medicine, Research & Experimental
Chunzhu Li, Chuan Xing, Jiaqi Zhang, Han Zhao, Wenjing Shi, Bing He
Summary: The research showed that time-restricted feeding can help women with anovulatory PCOS to lose weight, reduce body fat, improve menstrual irregularity, hyperandrogenemia, insulin resistance, and chronic inflammation.
JOURNAL OF TRANSLATIONAL MEDICINE
(2021)
Review
Endocrinology & Metabolism
Ioannis G. Lempesis, Samuel J. Apple, Gustavo Duarte, Leonidas Palaiodimos, Dimitrios Rafail Kalaitzopoulos, Maria Dalamaga, Damianos G. Kokkinidis
Summary: Polycystic ovary syndrome (PCOS) is a complex endocrinopathy that affects many women of reproductive age, involving hyperandrogenemia and insulin resistance. SGLT2 inhibitors (SGLT-2i) are a potential novel treatment option for PCOS, offering improvements in hormonal and metabolic parameters. Studies have shown reductions in body mass index, waist and hip circumference, fat mass, as well as improvements in insulin and androgen levels and blood pressure. This review aims to summarize the manifestations and mechanisms of PCOS-related cardiovascular disease and critically analyze the cardiometabolic and hormonal outcomes of recent studies on SGLT2i use in women with PCOS.
DIABETES-METABOLISM RESEARCH AND REVIEWS
(2023)
